ライフサイエンスコーパス: ITP

1 ITP accelerates the reaction kinetics as the ionic space

2 ITP has been largely used in traditional capillary based

3 ITP improves the LoD of LFA to the level of some lab-bas

4 ITP preconcentration accelerates the affinity reaction,

5 ITP simultaneously preconcentrates an analyte and purifi

6 ITP was more frequent among males in these subgroups.

7 ITP-enhanced LFA (ITP-LF) also shows up to 30% target ex

8 TFHs within the spleen of 8 controls and 13 ITP patients.

9 As compared with a historical cohort of 183 ITP patients, matched on the calendar year of ITP diagno

10 hout agonist stimulation was evaluated in 57 ITP patients (median age, 9.9 years).

11 e reported in 10.1% TTP, 7.1% HIT, and 25.8% ITP admissions.

12 ow-level light treatment (LLLT) to alleviate ITP in mice.

13 in vitro predicted its ability to ameliorate ITP.

14 Of these 8 antibodies, only 5 ameliorated ITP.

15 t phagocytosis in vitro also all ameliorated ITP in vivo.

16 agocytosis in vitro successfully ameliorated ITP in vivo.

17 flame retardant mixtures: FM 550, FM 600, an ITP mixture, and a TBPP mixture.

18 ed all consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy.

19 tion from 1 pg muL(-1) to 100 pg muL(-1) and ITP velocity over the range of 10-50 mum s(-1), and ther

20 Under an anionic ITP condition, the device showed superior performance in

21 ally applicable to both cationic and anionic ITP assays and likely to a wide range of sample species.

22 g (13.40%) for MN in combination with anodal ITP (p<0.001).

23 The purpose of this study was to assess ITP incidence at a nationwide level (France) with recent

24 stinal or central nervous system bleeding at ITP onset was rare (<1%).

25 The IWG now proposes a consensus-based ITP-specific bleeding assessment tool (ITP-BAT) with def

26 Paper based ITP is challenged by Joule heating and evaporation becau

27 22 regulated microRNA that differed between ITP patients and controls.

28 We discuss the similarities between ITP and EFGF and describe promising possibilities to tra

29 at the latrodectin 2 gene and nearly all CHH/ITP genes include a phase 2 intron in the same position,

30 corpion and wasp venom cDNAs, as well as CHH/ITP neuropeptides, show latrodectins as derived members

31 These analyses suggest that CHH/ITP homologs are more widespread in spider venoms, and w

32 rting latrodectin's placement within the CHH/ITP superfamily.

33 w latrodectins as derived members of the CHH/ITP superfamily.

34 n of patients with newly diagnosed childhood ITP.

35 the ASH management guidelines for childhood ITP.

36 enous immunoglobulin alone developed chronic ITP less often (OR 0.39, 95% CI 0.28-0.54 and OR 0.71, 9

37 nib in relation to other options for chronic ITP.

38 is related to bleeding phenotype in chronic ITP.

39 The following predictors of chronic ITP in children, assessed in at least 3 studies, have be

40 a-analysis to identify predictors of chronic ITP.

41 id option for treating persistent or chronic ITP in adults.

42 imab to splenectomy in persistent or chronic ITP patients.

43 well-defined cohort of 33 pediatric chronic ITP patients.

44 Thus, our data indicate that chronic ITP in childhood is a separate disease entity, dissimila

45 diagnosed children and children with chronic ITP.

46 L-4 in newly diagnosed compared with chronic ITP.

47 Using this chip, we compared ITP-based surface hybridization to standard continuous f

48 (34%) of 101 patients receiving concomitant ITP medication discontinued 1 or more medication.

49 ases, mostly in combination with concomitant ITP therapy (70% of responders).

50 m data from the Intercontinental Cooperative ITP Study Group Registry II focusing on natural history,

51 low that opposes the ITP motion (counterflow ITP mode).

52 r the spatiotemporal behavior of the coupled ITP and affinity process, and for key figures of merit,

53 at mitigates this damage by conversion of (d)ITP to monophosphate, ITPA, has been proposed as a possi

54 triphosphates, resulting in formation of (d)ITP, can be deleterious, leading to DNA damage, mutagene

55 ntal validation of our model and demonstrate ITP-AC separation of the target from 10,000-fold more-ab

56 We demonstrate ITP-AC with 25 nt, Cy5 labeled DNA target and a DNA prob

57 a numerical and analytical model to describe ITP spacer assays, which involve low-mobility, nonfocusi

58 ciated with an observable risk of developing ITP.

59 change in the management of newly diagnosed ITP at a pediatric care tertiary care hospital in the Un

60 days 5-32) in 12 adults with newly diagnosed ITP in an outpatient setting.

61 n about practice patterns of newly diagnosed ITP in the United States.

62 311 pediatric patients with newly diagnosed ITP managed between January 1, 2007, and December 31, 20

63 the driving electric field (stop-and-diffuse ITP mode) or applying a counter flow that opposes the IT

64 Finally, we applied FASS-ITP-CE for the simultaneous detection of two miRNAs in c

65 e demonstrated that preconcentration by FASS-ITP could be combined with the CE-based separation of th

66 We proved that FASS-ITP could retain and concentrate both near-neutral PNA w

67 f a median of 10.5 prior treatment lines for ITP (range, 6-15).

68 No associations were significant for ITP.

69 patients who have undergone splenectomy for ITP reveals significant potential risks that should be d

70 We observed that splenectomy for ITP second-line treatment was more effective than Rituxi

71 ethasone is a feasible frontline therapy for ITP.

72 ent, has become the first-line treatment for ITP; however, patients with refractory disease usually r

73 antibody [mAb]) is one of the treatments for ITP and is known to deplete B cells but may also work by

74 us, transfer of antiplatelet antibodies from ITP mothers by breastfeeding can be associated with pers

75 nalyses of mRNA and microRNA in T cells from ITP patients and controls.

76 The THD-modulated MSCs from ITP patients induced mature DCs to become tolerogenic DC

77 The study reveals the inability of MSCs from ITP patients to induce tolerogenic ability in DCs.

78 ncy; R-ITP group, 6 women who recovered from ITP before pregnancy; and 9 healthy controls.

79 ed role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy w

80 Furthermore, ITP-AC separates the target and contaminants into nondif

81 groups of women: ITP group, 7 women who had ITP during pregnancy; R-ITP group, 6 women who recovered

82 luding target distribution width and height, ITP zone velocity, forward and reverse reaction constant

83 vant ITP-AC regimes, and it demonstrates how ITP greatly reduces assay time and improves column utili

84 Utilizing these unique mAbs and human ITP plasma, we find that anti-GPIbalpha, but not anti-GP

85 Importantly, ITP-DQAMmiR can be performed in a fully automated mode u

86 ammaR interaction, had been shown to improve ITP in refractory human patients.

87 increased plasma levels of interleukin-21 in ITP.

88 the secretion of antiplatelet antibodies in ITP patients.

89 e an activation of splenic CD8(+) T cells in ITP patients who did not respond to RTX and suggest thei

90 -mimetic drugs that raise platelet counts in ITP patients.

91 ea that platelet production was defective in ITP was superseded or ignored for decades, but it has no

92 RECENT FINDINGS: In ITP, more studies are providing evidence of TPO-RA effic

93 rmine if differences in platelet function in ITP patients account for this variation in bleeding tend

94 controls, splenic TFH frequency is higher in ITP patients and correlates with germinal center and pla

95 We found no evidence of an increase in ITP after vaccination in the previous 6 or 12 months (ad

96 oRNA target genes significantly increased in ITP.

97 e platelet production from megakaryocytes in ITP in 1915.

98 ectiveness of the thrombopoietin mimetics in ITP.

99 We demonstrated that MSCs in ITP patients had reduced proliferative capacity and lost

100 ent description of the bleeding phenotype in ITP, and the IWG unanimously supports its adoption and v

101 be useful markers of future bleeding risk in ITP.

102 he mechanism of infection after rituximab in ITP patients.

103 e the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had b

104 ociated with concurrent bleeding severity in ITP.

105 of IL-21 and CD40 as therapeutic targets in ITP.

106 results point out the involvement of TFH in ITP pathophysiology and the potential interest of IL-21

107 atelet production in WAS/XLT is less than in ITP, eltrombopag has beneficial effects on platelet coun

108 vel combination of conventional therapies in ITP given over 4 weeks.

109 lecules involved in the loss of tolerance in ITP.

110 Eltrombopag is active and well tolerated in ITP secondary to LPDs.

111 uld likely be candidates for clinical use in ITP.

112 mophilus influenzae type b (Hib) vaccines in ITP patients.

113 We identified 3771 incident ITP patients.

114 dy quantified the contribution of individual ITP and TBPP isomers in four commercial flame retardant

115 mbined immunodeficient (SCID) mice to induce ITP.

116 diagnosis of anti-GPIbalpha antibody-induced ITP.

117 plenocytes completely prevented CD61-induced ITP development.

118 into SCID mice with established CD61-induced ITP rescued the thrombocytopenia.

119 nsfusions affected antiplatelet CD61-induced ITP.

120 Isotachophoresis (ITP) and electric field gradient focusing (EFGF) are two

121 sing electrical lysing and isotachophoresis (ITP).

122 ocusing technique known as isotachophoresis (ITP) implemented on a microfluidic chip.

123 y developing a paper-based isotachophoresis (ITP) technology capable of 1) rapid isolation and identi

124 reaction is accelerated by isotachophoresis (ITP).

125 vel technique that couples isotachophoresis (ITP) with affinity chromatography (AC) to achieve rapid,

126 We leverage isotachophoresis (ITP), an electrophoretic focusing technique, to create a

127 in the design of peak-mode isotachophoresis (ITP) experiments.

128 mple location in peak mode isotachophoresis (ITP).

129 ental study of coupling of isotachophoresis (ITP) and affinity chromatography (AC) to effect rapid, s

130 investigate integration of isotachophoresis (ITP), an electrokinetic preconcentration and extraction

131 reconcentration technique, isotachophoresis (ITP).

132 , which do not focus under isotachophoresis (ITP) unless bound to their target sequence.

133 We use isotachophoresis (ITP) to preconcentrate and co-focus target molecules and

134 Here, we use isotachophoresis (ITP), a powerful electrokinetic preconcentration and sep

135 We used isotachophoresis (ITP) coupled with an ionic spacer to both react and sepa

136 ccelerated reactions using isotachophoresis (ITP), revealing new regimes of operation which in turn e

137 from complex samples using isotachophoresis (ITP).

138 face-based reactions using isotachophoresis (ITP).

139 ample stacking (FASS) with isotachophoresis (ITP).

140 ITP-enhanced LFA (ITP-LF) also shows up to 30% target extraction from 100

141 or corticosteroids for treatment of maternal ITP.

142 ty of CD8(+) T cells to activate and mediate ITP.

143 hese results indicate that antibody-mediated ITP is resistant to allogeneic platelet transfusions, wh

144 were transferred to induce antibody-mediated ITP, both CD61(+) platelet immunizations generated immun

145 ion (Bdep) therapy on CD8(+) T-cell-mediated ITP using a murine model.

146 with CD61(+) platelets, and T-cell-mediated ITP was initiated by transfer of their splenocytes into

147 s were transferred to induce T-cell-mediated ITP, transfer of allogeneic MHC-immunized splenocytes co

148 anti-GPIbalpha (but not GPIIbIIIa)-mediated ITP is often refractory to therapies targeting FcgammaR

149 eaction times of 30 min, we show that 20 min ITP hybridization can achieve 5.3-fold higher sensitivit

150 ruited into the ITP zone by higher-mobility, ITP-focused probes.

151 arameters in the optimal design of peak-mode ITP assays and highlight regimes of particular interest.

152 ituted isopropylated triaryl phosphate (mono-ITP).

153 In vivo, in a mouse ITP model we observed a short half-life of hexameric-Fc

154 In conclusion, multirefractory ITP was associated with high morbidity and mortality.

155 h a 5:1 ratio, patients with multirefractory ITP were more likely to have secondary ITP (odds ratio [

156 we included 37 patients with multirefractory ITP, defined as no response to splenectomy, rituximab, r

157 atically inhibited antibody-dependent murine ITP and successfully circumvented the inflammatory respo

158 linked to murine albumin in a passive murine ITP model.

159 erapy may be beneficial in antibody-negative ITP.

160 We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte pola

161 However, 60% of ITP patients do not respond to RTX.

162 t a sufficient condition for amelioration of ITP but that the antibody's ability to prevent platelet

163 nofluidics, many interesting combinations of ITP and EFGF features can be achieved, yielding powerful

164 Throughout the course of ITP, 5/37 patients died, 3 with ITP (bleeding, n = 2; se

165 organ donors had a predonation diagnosis of ITP.

166 The median duration of ITP before being recognized as multirefractory was 78 mo

167 lytical model for spatiotemporal dynamics of ITP-AC.

168 unizations as possible triggering factors of ITP through molecular mimicry.

169 majority of pregnant women with a history of ITP did not require treatment, and neonatal outcomes wer

170 in that it contained TBPP isomers instead of ITP isomers.

171 idelines for the diagnosis and management of ITP and standards for terminology.

172 study was to discern whether breast milk of ITP mothers contained antiplatelet antibodies causing pe

173 of the immunoglobulin A type in the milk of ITP patients compared with the other 2 groups.

174 safe, simple, and cost-effective modality of ITP.

175 will help us understand the pathogenesis of ITP, and with appropriate safeguards, THD may benefit pa

176 of mitochondrial stress to the pathology of ITP, but also clinical potentials of LLLT as a safe, sim

177 d thrombopoiesis, but the pathophysiology of ITP has yet to be fully delineated.

178 These results highlight the potential of ITP to increase the sensitivity of paper based LFIA unde

179 technology integrates the focusing power of ITP and the multiplex capability of paper-based lateral

180 improvement of the signal-to-noise ratio of ITP-based genotypic assays.

181 astly, we demonstrate that the resolution of ITP-AC increases linearly with time and purify 25 nt tar

182 n (IVIg) and corticosteroids in treatment of ITP.

183 We demonstrate the use of ITP to preconcentrate and deliver target proteins to a s

184 eled species for application in a variety of ITP assays.

185 TP patients, matched on the calendar year of ITP diagnosis with a 5:1 ratio, patients with multirefra

186 P), the International Working Group (IWG) on ITP acknowledged that response to treatment should consi

187 P specificity of RtcB such that ATP, dGTP or ITP is used efficiently.

188 il bleeding time when applied to two passive ITP models induced by anti-CD41 antibody.

189 e (CHH) and arthropod Ion Transport Peptide (ITP) superfamily for venom expression in black widow spi

190 the expression of the ion transport peptide (ITP) to be consistent within the fifth sLN(v) and one do

191 e provide a detailed protocol for performing ITP-AC and describe the design of a buffer system to per

192 phosphate (B2IPPPP) being the most prevalent ITP isomers in both mixtures.

193 All patients had received previous ITP treatments.

194 hat, in idiopathic thrombocytopenic purpura (ITP), production of platelets from megakaryocytes is def

195 eatment for immune thrombocytopenic purpura (ITP).

196 a (HIT) and immune thrombocytopenic purpura (ITP).

197 oup, 7 women who had ITP during pregnancy; R-ITP group, 6 women who recovered from ITP before pregnan

198 peutic target in the treatment of refractory ITP.

199 use of Tpo-RAs for severe and/or refractory ITP during pregnancy seems safe for both mother and neon

200 capture length and capture time in relevant ITP-AC regimes, and it demonstrates how ITP greatly redu

201 une causes of thrombocytopenia and secondary ITP.

202 ctory ITP were more likely to have secondary ITP (odds ratio [OR], 4.84; 95% confidence interval [CI]

203 egnancy, including 2 patients with secondary ITP, were analyzed.

204 s common in patients with moderate to severe ITP.

205 cus target molecules and beads into a single ITP zone.

206 bridized cell-probe complexes in a two-stage ITP method.

207 t occurred with the lower-affinity substrate ITP, which could not be explained by an increase in subs

208 whereas 4 had chronic refractory symptomatic ITP and 3 were receiving eltrombopag when pregnancy star

209 Transient isotachophoresis (t-ITP) was introduced in this work as an electrokineticall

210 We conclude that ITP patients post splenectomy are at increased risk for

211 We show that ITP can achieve approximately the same sensitivity as a

212 We show that ITP is able to improve the limit of detection (LoD) of L

213 Our findings show that ITP on nitrocellulose is capable of up to a 900 fold inc

214 We show that ITP on the nitrocellulose membrane can be powered and ru

215 Our data support that ITP is a benign condition for most affected children and

216 tive incidence of sepsis was 11.1% among the ITP patients who underwent splenectomy and 10.1% among t

217 suggest similarities between FM 550 and the ITP mixture, with 2-isopropylphenyl diphenyl phosphate (

218 op-mediated isothermal amplification and the ITP-enhanced CRISPR assay to achieve detection of severe

219 annel, which exhibits sharp decreases as the ITP interface moves more rapidly through the higher curr

220 the focused analyte is bound in space by the ITP interface and, upon reaction with the surface, conti

221 focusing targets that are recruited into the ITP zone by higher-mobility, ITP-focused probes.

222 rictions and on detecting the passage of the ITP interface through these constrictions.

223 arry out an experimental optimization of the ITP-based immunoassay and demonstrate a 1300-fold improv

224 or applying a counter flow that opposes the ITP motion (counterflow ITP mode).

225 We here combine this ITP purification with loop-mediated isothermal amplifica

226 the pathogenesis of immune thrombocytopenia (ITP) and identify a novel mechanism by which high-dose d

227 imab (RTX) to treat immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), resp

228 T) from donors with immune thrombocytopenia (ITP) can result in significant bleeding complications in

229 Patients with immune thrombocytopenia (ITP) commonly have antiplatelet antibodies that cause th

230 Management of immune thrombocytopenia (ITP) during pregnancy can be challenging because treatme

231 role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 anti

232 reatment of primary immune thrombocytopenia (ITP) have recently emerged.

233 reatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1

234 eatment options for immune thrombocytopenia (ITP) in pregnancy are limited, and evidence to guide man

235 Immune thrombocytopenia (ITP) in pregnant women can cause neonatal thrombocytopen

236 chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding.

237 up of children with immune thrombocytopenia (ITP) indicates that the majority undergo remission and s

238 Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by a

239 Primary immune thrombocytopenia (ITP) is a disorder caused by autoantibody-mediated plate

240 Childhood immune thrombocytopenia (ITP) is a rare autoimmune bleeding disorder.

241 Immune thrombocytopenia (ITP) is an acquired bleeding disorder characterized by a

242 Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with a complex p

243 Immune thrombocytopenia (ITP) is an autoimmune disease where platelets are destro

244 Immune thrombocytopenia (ITP) is an autoimmune disease with a complex heterogeneo

245 Immune thrombocytopenia (ITP) is an autoimmune disorder in which impaired mesench

246 Immune thrombocytopenia (ITP) is an immune-mediated acquired bleeding disorder ch

247 The epidemiology of immune thrombocytopenia (ITP) is not well known.

248 ening hemorrhage in immune thrombocytopenia (ITP) must be balanced against adverse effects of therapi

249 Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in vari

250 play a key role in immune thrombocytopenia (ITP) pathogenesis; however, little is known about T-cell

251 Immune thrombocytopenia (ITP) patients with similarly low platelet counts differ

252 7 pediatric chronic immune thrombocytopenia (ITP) patients.

253 gement of childhood immune thrombocytopenia (ITP) recommending management with observation alone when

254 Immune thrombocytopenia (ITP) results from platelet destruction and production su

255 Immune thrombocytopenia (ITP) secondary to chronic lymphoproliferative disorders

256 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety.

257 Refractory immune thrombocytopenia (ITP) was previously defined as lack of a minimum respons

258 adults with primary immune thrombocytopenia (ITP) who do not respond to, cannot tolerate, or are unwi

259 Patients with immune thrombocytopenia (ITP) who relapse after an initial trial of corticosteroi

260 adults with primary immune thrombocytopenia (ITP), addition of rituximab (RTX) to high-dose dexametha

261 utcome criteria for immune thrombocytopenia (ITP), the International Working Group (IWG) on ITP ackno

262 role of microRNA in immune thrombocytopenia (ITP), we performed genome-wide expression analyses of mR

263 d-line treatment in immune thrombocytopenia (ITP).

264 e disorder known as immune thrombocytopenia (ITP).

265 n antibody-mediated immune thrombocytopenia (ITP).

266 sk in patients with immune thrombocytopenia (ITP).

267 st-line therapy for immune thrombocytopenia (ITP).

268 n a murine model of immune thrombocytopenia (ITP).1 The unique aspect of this protein is that it bloc

269 based ITP-specific bleeding assessment tool (ITP-BAT) with definitions and terminology consistent wit

270 iction of the rate of surface reaction under ITP and can be used to design and optimize such assays a

271 e of antibody-secreting cells from untreated ITP spleens and from healthy tissues.

272 long-lived PC were not detected in untreated ITP spleens.

273 compared with 11 spleens from RTX-untreated ITP patients and 9 controls.

274 e pyrophosphorylase, SVEN_3972 is an unusual ITP-mannose pyrophosphorylase, and SVEN_2781 is a pyroph

275 evious CRISPR diagnostic assays, we also use ITP for automated purification of target RNA from raw na

276 We use ITP to focus a sample of interest and deliver a high con

277 tion rates, the latter in applications where ITP is used to accelerate chemical reactions.

278 he course of ITP, 5/37 patients died, 3 with ITP (bleeding, n = 2; sepsis n = 1); 15 (40%) had at lea

279 ions with TTP; 6332 with HIT and 79 980 with ITP.

280 y and efficacy of eltrombopag in adults with ITP who had completed a previous eltrombopag study.

281 at 1 year was significantly associated with ITP duration <1 year (P = .02) and previous transient co

282 Strong associations with ITP duration may reflect CMB accrual over time or more r

283 T if they receive an organ from a donor with ITP is unknown.

284 liver transplant recipients from donors with ITP compared with liver transplant recipients from donor

285 Organs from donors with ITP may be considered for transplantation, but livers sh

286 cipients of organs from deceased donors with ITP recorded in the UK Transplant Registry between 2000

287 Organs from donors with ITP resulted in 49 organ transplants (31 kidney, 14 live

288 tional prospective study of 49 patients with ITP and nadir platelet counts <30 x 109/L and 18 aged-ma

289 and reducing bleeding in most patients with ITP of more than 6 months' duration.

290 rospective 24-week study in 18 patients with ITP secondary to LPDs to assess the safety and efficacy

291 Patients with ITP treated with rituximab who achieved CRs and PRs (pla

292 ere detected in the spleens of patients with ITP up to 6 months after rituximab treatment, and the PC

293 we identified a cohort of 9976 patients with ITP, 1762 of whom underwent splenectomy.

294 s-sectional study of pediatric patients with ITP.

295 te safeguards, THD may benefit patients with ITP.

296 dentified in 43% (21 of 49) of patients with ITP; prevalence increased with decreasing nadir platelet

297 28-day phase 2 study assigned subjects with ITP of >/=3 months to once-daily oral avatrombopag (2.5,

298 Results from 15 pregnant women with ITP (pregnancies, n = 17; neonates, n = 18) treated with

299 er transplant recipients from donors without ITP (64% vs. 85%, p = 0.012).

300 llected milk samples from 3 groups of women: ITP group, 7 women who had ITP during pregnancy; R-ITP g